Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2008

01-12-2008 | Original Paper

It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese Patients

Authors: Motoyasu Kusano, Naohito Shirai, Kanako Yamaguchi, Michio Hongo, Tsutomu Chiba, Yoshikazu Kinoshita, The Acid-Related Symptom (ARS) Research Group

Published in: Digestive Diseases and Sciences | Issue 12/2008

Login to get access

Abstract

The hypothesis that non-erosive reflux disease (NERD) patients comprise various subgroups is gaining popularity. This study was conducted to investigate the possibility of categorizing NERD patients according to symptom types and response to acid-suppressive drug rabeprazole (RPZ) 10 mg/day. NERD patients were classified as grade N (endoscopically normal), M (minimal change), or erosive GERD, and answered a 51-item, yes-or-no questionnaire pre and post-treatment. Compared to erosive GERD, clear differences existed in pretreatment prevalence of symptoms and responsiveness to RPZ in grades N and M; the results suggested stomachaches (especially at night) were significant symptoms in grade N and dysmotility-like symptoms like bloated stomach were significant in grade M while gastroesophageal reflux symptoms were significant in erosive GERD. Clinical significance of classifying NERD was indicated from different symptoms and responsiveness to PPI.
Appendix
Available only for authorised users
Literature
1.
Dent J, Brun J, Fendrick A, Fennerty M, Janssens J, Kahrilas P, Lauritsen K, Reynolds J, Shaw M, Talley N, The Genval Workshop Group (1999) An evidence-based appraisal of reflux disease management—the Genval Workshop Report. Gut 44(Suppl 2):S1–16CrossRef
2.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group (2006) The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101:1900–1920PubMedCrossRef
3.
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis. Gastroenterology 112:1798–1810PubMedCrossRef
4.
van Pixteren B, Numans ME, Bonis PA, Lau J (2006) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 19:CD002095
5.
Tendler DA, Parker RA, Spechler SJ (1996) Heartburn: ethnic variations in prevalence and interpretation. Gastroenterology 110:A276
6.
Fass R (2003) Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 98(Suppl 3):S2–S7PubMedCrossRef
7.
Bate CM, Green JR, Axon AT, Murray FE, Tildesley G, Emmas CE, Taylor MD (1997) Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 11:755–763PubMedCrossRef
8.
Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML (1997) Omeprazole 10 milligrams once daily, Omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease-in general practice. Scand J Gastroenterol 32:765–773
9.
Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Sugiyama T, Toki M, Ohwada T, Mori M (2004) Development and evaluation of FSSG; frequency scale for the symptoms of GERD. J Gastroenterol 39:888–891PubMedCrossRef
10.
Adachi K, Matsumori Y, Fujisawa T, Kamada T, Kusaka M, Ohumi T, Iwakiri R, Yamaguchi K, Danjo A, Hori K, Tomita T, Hayashi T, Haruma K, Fujimoto K, Miwa H, Kinoshita Y (2006) Symptom diversity of patients with reflux esophagitis: effect of omeprazole treatment. J Clin Biochem Nutr 39:46–54CrossRef
11.
Kahrilas PJ (2003) Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 98(Suppl 3):S15–S23PubMedCrossRef
12.
Hoshihara Y (2004) Endoscopic findings of GERD. Nippon Rinsho 62:1459–1464PubMed
13.
Nakamura T, Shirakawa K, Masuyama H, Sugaya H, Hiraishi H, Terano A (2005) Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther 21:19–26PubMedCrossRef
14.
Hongo M (2006) Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol 41:95–99PubMedCrossRef
15.
Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S (2002) Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Aliment Pharmacol Ther 97:1332–1339
16.
Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL (2005) Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol 11:3091–3098PubMed
17.
Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H, Yagi J, Komazawa Y, Mihara T, Katsube T, Fujishiro H, Shizuku T, Hattori S, Yamamoto S, Kinoshita Y (2003) Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 18:1392–1398PubMedCrossRef
18.
Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators (2002) Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 16:445–454PubMedCrossRef
19.
Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL (2002) A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 16:479–485PubMedCrossRef
20.
Fujiwara Y, Higuchi K, Shiba M, Yamamori K, Watanabe Y, Sasaki E, Tominaga K, Watanabe T, Oshitani N, Arakawa T (2005) Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol 100:754–758PubMedCrossRef
21.
Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448–1456PubMedCrossRef
22.
Lee KJ, Vos R, Janssens J, Tack J (2004) Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol 286:G278–G284PubMedCrossRef
23.
Jones RH, Baxter G (1997) Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 11:541–546PubMedCrossRef
24.
Jones RH, Crouch SL (1999) Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 13:413–419PubMedCrossRef
25.
Joh T, Miwa H, Higuchi K, Shimatani T, Manabe N, Adachi K, Wada T, Sasaki M, Fujiwara Y, Hongo M, Chiba T, Kinoshita Y, ARS Research Group (2007) Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol 42:444–449PubMedCrossRef
26.
Keohane J, Quigley EM (2006) Functional dyspepsia and non-erosive reflux disease: a review. Minerva Gastroenterol Dietol 52:261–267PubMed
27.
Quigley EM (2004) Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol 18:695–706PubMedCrossRef
28.
Suzuki H, Nishizawa T, Hibi T (2006) Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 41:513–523PubMedCrossRef
29.
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V (2006) Functional gastroduodenal disorders. Gastroenterology 130:1466–1479PubMedCrossRef
30.
Shimoyama Y, Kusano M, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Moki F, Sugiyama T, Toki M, Ohwada T, Mori M (2005) Diagnosis of gastroesophageal reflux disease using a new questionnaire. J Gastroenterol Hepatol 20:643–647PubMedCrossRef
Metadata
Title
It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese Patients
Authors
Motoyasu Kusano
Naohito Shirai
Kanako Yamaguchi
Michio Hongo
Tsutomu Chiba
Yoshikazu Kinoshita
The Acid-Related Symptom (ARS) Research Group
Publication date
01-12-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0290-2

Other articles of this Issue 12/2008

Digestive Diseases and Sciences 12/2008 Go to the issue

Original Paper

Deterioration of Muscle Function in the Human Esophagus with Age

Original Paper

Effects of Proteoglycan on Dextran Sulfate Sodium-Induced Experimental Colitis in Rats

Original Paper

Psychological Factors in Gastroesophageal Reflux Disease Measured by SCL-90-R Questionnaire

CASE REPORT

Interruption of Mesalamine and Reduction of the Blood Concentration of the Active Metabolites of Azathioprine: Possible Causes of Ulcerative Colitis Relapse

Case Report

A Case Report of Idiopathic Cecal Ulcer Mimicking Cecal Cancer

Original Paper

NERD, GERD, and Barrett’s Esophagus: Role of Acid and Non-acid Reflux Revisited with Combined pH-Impedance Monitoring
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits